51.   This past year has been particularly punishing as biotech stocks have fallen from favor and investment fiascos such as Imclone Systems and Enron Corp. grab headlines.

52.   This year, biotech stocks have fallen along with Nasdaq.

53.   Volatility aside, biotech stocks fared well last year, peaking during the excitement over the human genome project in March.

54.   When Clinton and British Prime Minister Tony Blair commented on patenting genes in April, biotech stocks plummeted.

55.   While most biotech stocks have been stagnant, Genentech has been making steady gains as product after product scored well in late-stage clinical trials.

56.   While most of the stock market was in a summer swoon, biotech stocks staged a strong rally in the third quarter, according to two new studies.

57.   With most biotech stocks sitting out the bull market, the success put Agouron on the map.

58.   A few years ago, biotech stocks were all rage in the US and now they have given away to tech stocks.

59.   As biotech stocks fell, other technology groups succumbed to profit-taking.

60.   Biotech stocks also did well, thanks to defense-related spending.